Search research articles
Contact Us
Filters
Showing results (71-80 of 115) with videos related to
Page
of 12
Sort By:
Techniques in Coloproctology
|
July 30, 2017
Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study
A Barina, A De Paoli, P Delrio, et al.
ESMO Open
|
September 2, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients
A Pretta, V Nasca, F Marmorino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
ESMO Open
|
March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
B Borelli, E Fontana, M Giordano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
S Kopetz, J Tabernero, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
ESMO Open
|
February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
S Stintzing, J Tabernero, T Satoh, et al.
ESMO Gastrointestinal Oncology
|
April 23, 2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
M Fakih, S Gill, K Sampat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 115) with videos related to
Sort By:
Page
of 12
Techniques in Coloproctology
|
July 30, 2017
Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study
A Barina, A De Paoli, P Delrio, et al.
ESMO Open
|
September 2, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients
A Pretta, V Nasca, F Marmorino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
ESMO Open
|
March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
B Borelli, E Fontana, M Giordano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
S Kopetz, J Tabernero, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
ESMO Open
|
February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
S Stintzing, J Tabernero, T Satoh, et al.
ESMO Gastrointestinal Oncology
|
April 23, 2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
M Fakih, S Gill, K Sampat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Page
of 12